For the latest openings visit the Careers section of our website CPL Biologicals launches Cadiflu-S,World`s First Virus Like Particle(VLP) Vaccine for Seasonal Influenza
For the latest openings visit the Careers section of our website CPL Biologicals launches Cadiflu-S,World`s First Virus Like Particle(VLP) Vaccine for Seasonal Influenza

News & Events

  • CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza Read More >>
Highlights
  • Cadiflu-S is India’s first indigenously developed vaccine for seasonal influenza
  • First Virus Free seasonal influenza vaccine in India: a major breakthrough
  • Vaccine with least chances of allergies since the vaccine does not contain egg proteins, antibiotics or preservatives
Ahmedabad, Nov 17, 2016:

CPL Biologicals Pvt. Ltd, a joint-venture biotechnology company of Cadila Pharmaceuticals Ltd, India and Novavax Inc., USA, has become the first company in India to indigenously develop ‘Cadiflu-S’, a vaccine for Seasonal Influenza. Responding to the Government of India’s initiative of ‘Make in India’ campaign, the Ahmedabad based company launched ‘Cadiflu-S’, which is also the first Virus Like Particles (VLP) technology based Influenza vaccine in the world.

The company has set up the vaccine facility at Dholka near Ahmedabad in Gujarat, India, with an initial investment of Rs. 100 crore. The plant has the capability of producing up to 25 million doses of vaccine every year.

‘Cadiflu-S’ does not contain any viruses, and is a major technological breakthrough since it completely eliminates the possibility of any infection to the vaccinated person from the vaccine. The viruses present in other available vaccines can, at times, replicate in human body thereby causing disease by the vaccine itself. Moreover, the VLP based vaccine does not contain any egg proteins, antibiotics or preservatives, and thus provides huge relief to people who are prone to allergies. The indigenous production of ‘Cadiflu-S’ for seasonal influenza will provide a major boost to the government’s initiative of preventing any probability of pandemic flu-like situation. The seasonal vaccine which is supposed to be administered every year due to changing strains of the virus, protects even healthy individuals, both children and adults, from the influenza which at times could lead to other highly infectious and chronic illnesses. The seasonal influenza virus affects the lungs and other areas of the respiratory tract. People with chronic conditions of Cardiac Ailments, Diabetes Mellitus, Metabolic Diseases, Renal Failure and Asthma run a high risk of developing complications.

‘Cadiflu-S’ is developed by incorporating the gene sequences of multiple immunogenic proteins (HA, NA and M1 antigens) of Influenza virus to produce a complex envelope Virus Like Particle vaccine. Each dose of the recombinant baculovirus-based vaccine, Cadiflu-S (0.5 ml) contains three strains of flu viruses namely, A/California/7/2009 (H1N1)-like virus, A/HongKong/4801/2014 (H3N2)-like virus, B/Brisbane/60/2008-like virus. World Health Organisation (WHO) in Feb 2016 recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season.  The current market for Seasonal Influenza vaccine in India is estimated at 2 – 2.5 million dosages per year and is rapidly growing.

Commenting on the launch, Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd. said, “Building on the success of ‘Cadiflu-S’, we will be launching a series of vaccines, including many first-of-its kind in the world, using Novel technology platforms like VLPs and Nanoparticles. The VLP technology provides us a huge edge as it takes only 12-14 weeks to develop the new strain specific vaccine, as against 24 to 32 weeks for the development of a conventional vaccine. If there is a necessity tomorrow, we can launch other types of pandemic flu vaccines, like H7N9 vaccines at a much faster pace compared to conventional vaccines.”

Dr. James F. Young, Chairman, Novavax Inc, said, “We have successfully completed Phase III trials at 10 centers across India to evaluate the Immunogenicity and Safety of this Seasonal Influenza Virus-Like Particle (VLP) Vaccine. ‘Cadiflu-S’ has received Drugs Controller General of India’s (DCGI) approval for launching the vaccine in India. We have also developed a strong pipeline that include Rabies 3 dose vaccine, Pancreatic Cancer vaccine, Rabies single dose vaccine, Hepatitis E vaccine, Varicella zoster virus vaccine and Human Papilloma vaccine.”

CPL Biologicals has obtained all the necessary approvals from the concerned regulatory authorities for commercialisation of ‘Cadiflu-S’ vaccine. Apart from the Indian markets, the company will also be looking to cater to the Middle East and South East Asian markets in coming years.

About CPL Biologicals Pvt. Ltd – www.cplbio.com

Based in Ahmedabad, India, CPL Biologicals Pvt. Ltd. is an independent joint-venture biotechnology company established in 2009 by Novavax Inc., USA and Cadila Pharmaceuticals Limited, one of India’s largest privately held pharmaceutical companies. The company develops prophylactic vaccines based on Novavax Inc’s Virus Like Particles (VLPs), recombinant nanoparticles and adjuvant technologies, which are groundbreaking innovations that improve global health through safe and effective vaccines. CPL Biologicals conducts end-to-end research, development and manufacturing based on these technologies in India.

For further information please contact:
Mukund Trivedy / Susim Mohanty
Cadila Pharmaceuticals Ltd  
Cell: 7573032251 / 9825413030               
Email:susim.mohanty@cadilapharma.co.in
Email:mukund.trivedy@cadilapharma.co.in

Gopal Modi/Rupesh Panchal
Adfactors PR, 
Cell: 9099030184/9925023103
Email:gopal.modi@adfactorspr.com
Email:rupesh.panchal@adfactorspr.com
Posted in Uncategorized
“The world is looking at PolycapTM, developed by Cadila Pharmaceuticals Ltd. We promise more such
firsts-in-the-world in times to come.”

 

                                                        – Shri I.A. Modi, Chairman

  • Research reveals PolycapTM reduced the risk of Coronary Heart Disease by 62% and Stroke by 48%
  • Findings were published in The Lancet, a refereed journal
  • The results were shared with thousands of Cardiologists at the Cardiology College’s Conference in Florida
“All over the world, response to the research findings on Polycap is overwhelming.

This is a proud moment for me as an Indian that an Indian Pharmaceutical company has worked hard to achieve this feat” said Shri I A Modi, Chairman of Cadila Pharmaceuticals, Ahmedabad while sharing the results of TIPS Study with media.

According to “The Indian Polycap Study (TIPS)” published in the latest edition of The Lancet, PolycapTM has shown to bring down the risk of coronary heart disease by 62% and stroke by 48%. Cardiovascular diseases, predominantly heart disease and stroke account for around 30% of all deaths around the world.

According to Shri Modi, “A typical patient of heart diseases needs to take more than 5-6 pills of different medications everyday for lifelong, putting immense burden of not only the illness but the treatment itself and has a negative effect on the quality of life of the individual.” The Polycap will also offer a big psychological advantage to patients. He further said that “there is no drug currently available which can be taken by individuals who are at high risk for these illnesses as a means of primary prevention”.

Elaborating on the composition and trials of Polycap, Shri Modi said that “PolycapTM, is a combination of 3 common antihypertensive drugs along with aspirin and a statin (cholesterol lowering drug). PolycapTM has been tested in over 2000 patients across 50 centers in India by one of the most respected clinical researchers Dr Salim Yusuf from McMaster University Canada”

According to the study published in The Lancet, “PolycapTM reduced multiple risk factors for cardiovascular diseases such as lowering the blood pressure, the heart rate, the lipids and decreasing the stickiness of the platelets”.
Participants had an average age of 54 years, with at least one risk factor for heart disease – high blood pressure, high cholesterol, obesity, diabetes or smoking. Compared to groups given no blood pressure medicines, those who got the polypill lowered their systolic blood pressure (the top number) by more than 7 units and their diastolic (the bottom number) by about 6 – comparable to levels for people who were given the three drugs without aspirin and the cholesterol drug.
LDL, or bad cholesterol, dropped 23 percent on the polypill versus 28 percent in those taking the statin drug separately. Triglycerides dropped 10 percent on the combo pill versus 20 percent with individual statin use. Neither pill affected levels of HDL, or good cholesterol. Anti-clotting effects seemed the same with the polypill as with aspirin alone. Side effect rates were the same for the polypill as for the five medicines individually.
“Formulating a single pill of five drugs that work in five different ways is a complex task – more complex than simply mixing the medicines. Pills have coatings and other ingredients that control the rate at which the medicine is released into the bloodstream. This also represents our R&D capabilities in Formulations Development” said Shri Modi.

Posted in Uncategorized
  • British Medical Journal (BMJ) carried an article in 2003 discussing a concept like Polycap as primary prevention of heart diseases
  • What was only a concept six years ago is today a reality with Cadila Pharmaceuticals taking a lead with its first-in-the-world Polycap
  • Cadila Pharmaceuticals conducted pharmacokinetic study to show the effects of each of five drugs combined in Polycap; recognized by leading journals
  • The silent killer, Cardiovascular Diseases take away precious lives in the age group of 45 years and above; the world was struggling to treat the cause, and prevention was never given a major focus 
  • Dr Salim Yusuf, of McMaster University, Canada, world-renowned cardiologist and the man behind the HOPE & INTERHEART Trials led the team of researchers on The Indian Polycap Studies (TIPS) Trials

 

NEW DELHI, MAY 9, 2009: Ahmedabad based pharma major; Cadila Pharmaceuticals today unveiled facts of TIPS (The Indian Polycap Study) which eventually led to the development of world’s first Polycap for primary prevention of heart diseases. Dr. Salim Yusuf – the principal investigator for TIPS and internationally renowned cardiologist – was in India to shed light on new horizons in the primary prevention of cardiovascular disease (CVD) after Polycap at a Symposium.

Cardiovascular diseases, predominantly heart disease and stroke account for around 30% of all deaths around the world. A near-healthy person who is at risk of heart diseases would need to take more than 5-6 pills of different medications everyday for the rest of his life; something that puts immense burden on an individual. The Polycap offers a big psychological advantage to such individuals. Currently no drug is available to individuals who are at high risk for these illnesses as a means of primary prevention.

PolycapTM is a combination of 3 common antihypertensive drugs along with aspirin and a statin (cholesterol lowering drug). PolycapTM has been tested in over 2000 subjects across 50 centers in India. According to “The Indian Polycap Study (TIPS)” published in The Lancet, PolycapTM is shown to bring down the risk of coronary heart disease by 62% and stroke by 48%.

Addressing media on the occasion of Polycap symposium, Mr. Indravadan Modi, Chairman of Cadila Pharmaceuticals Limited and doyen of Indian Pharmaceutical industry said that – “I have seen  the Indian Pharmaceutical Industry shaping up since independence. There was a time when even the Indian doctors were hesitant to prescribe medicines manufactured by Indian pharma company. Since then, the industry has come a long way. Polycap is the striking example. With Polycap, the new era for Indian Pharmaceutical industry has begun. Polycap has shown that the Indian Pharmaceutical Industry is now capable enough to offer “World’s First” kind of products. Research still is a challenge in our country  as recovery of cost remains under pressure due to socio-economic conditions and per capita affordability of the patient. It has been our commitment to make quality medicines affordable. And hence we decided to allocate funds for Polycap from our own resources.”

About Cadila Pharmaceuticals Limited

Cadila Pharmaceuticals Limited operates as a pharmaceutical company worldwide. It focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, biosynthesis, genetic engineering, vaccines, and immunoglobulins. Cadila Pharmaceuticals is the first Indian company to get US FDA approvals for clinical trials to be conducted in India. The company has filed five INDs with US FDA. The company’s diversified operations encompass hospital disposables and instrumentation, diagnostics, specialty chemicals, softgel, pharma machinery, and travel and leisure. Cadila Pharmaceuticals is setting up a pharma sector specific Special Economic Zone, PhaEZ Park near Ahmedabad in the vicinity of Dholera Special Investment Region and Delhi-Mumbai Investment Corridor. The company is based in Ahmedabad, India

http://www.cadilapharma.com

Posted in Uncategorized

Ahmedabad based pharmaceuticals major Cadila Pharmaceuticals Ltd. (CPL) today announced the launch of its joint venture with the US based vaccine company, Novavax as per the agreement signed between the two companies in March 2009. This new venture called “CPL Biologicals Pvt. Ltd.” will work in the area of development and manufacturing of therapeutic and prophylactic vaccines, biological therapeutics and diagnostics in India.

Mr. I. A. Modi, Chairman of CPL Biologicals, noted:  “This joint venture represents an important strategic alliance for vaccine development and manufacturing in India and uses unique and cutting-edge vaccine technology.  Our vision is to be a leading provider of high quality, affordable vaccines, biological therapeutics and diagnostics through world-class research and innovative manufacturing to address current and future global health challenges.”

The new joint venture (JV) will develop novel vaccines based on “Virus Like Particles” (VLP) using cutting edge technology. This technology significantly compresses vaccine manufacturing time as compared to the conventional methods. Furthermore, an additional feature about the VLP technology is that it mimics the virus without the ability to cause infection.

CPL Biologicals will establish manufacturing facilities in India to develop, produce and sell products such as influenza vaccine, and other novel vaccines based on VLP technology. Looking at the global spread of swine flu and the WHO’s announcement of declaring it as a pandemic, the swine flu vaccine is an urgent need. A special initial focus is to develop the pandemic H1N1 influenza vaccine candidate (Swine flu vaccine) in India that Novavax is developing in the United States.

The initial investment in CPL Biologicals is about Rs. 100 crores. Cadila Pharmaceuticals Ltd. (CPL) is also a significant shareholder in Novavax, Inc. USA and has a position on the Board of Directors of Novavax.

With this alliance, a new era in the field of vaccine development has started in India.  The company aims to produce and market biologicals in India before the end of the fiscal year 2009-10.

This strategic partnership will surely turn a new leaf in the pharma history of our nation.

About Cadila Pharmaceuticals Ltd.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. Cadila Pharmaceuticals is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and  immunologicals. The  state-of-the-art  Research  and Development (R&D) facility at
Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) approval by USFDA. The company has state-of-the-art manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia.
After Polycap- a novel and world’s first drug combination for primary prevention of Cardiovascular Heart Disease (CHD), Cadila Pharmaceuticals is on the World map.

About Novavax

Novavax, Inc. USA, a NASDAQ listed company, is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based potent, recombinant vaccines utilizing a new and efficient manufacturing approach.

Novavax is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. It has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu, Respiratory Syncytial Virus (RSV) and Varicella Zoster Virus (VZV). Having validated their approach in animals, they are now in clinical testing of pandemic and seasonal influenza vaccine.
Novavax follows a holistic approach to control the spread of disease. Using a unique manufacturing system that allows for rapid mass production, its long-term goal is to be able to rapidly deliver a customized vaccine in the midst of a pandemic.
M/s. Novavax is in the process of developing vaccines for RSV Herpes Zoster  and also plans to apply its particle-based vaccine approach to other viral diseases beyond influenza.
About VLP
With Virus Like Particle (VLP) Technology, Novavax has created the vaccines with structure similar to a virus but without the genetic material required for viral replication. Once injected into the body, VLPs trigger an immune response sufficient to protect a person if exposed to the virus.
VLPs have a number of advantages over traditional vaccines. Because they more closely match an individual viral strain, VLPs can trigger a more robust immune response. In addition, live virus is not needed to produce a VLP vaccine. Only the genetic sequence of the virus is required to quickly create a VLP vaccine against it. Because VLPs do not contain viral nucleic acids (DNA or RNA), they cannot replicate, and therefore, they present no threat of infection to a person being vaccinated.
The VLP is well suited to the development of vaccines against diseases endemic to India and surrounding regions like dengue fever, chikungunya fever. Dengue fever is a mosquito-borne disease, which has re-emerged in India and has a very high mortality rate. Currently, there is no vaccine or definitive treatment for Dengue fever.

Posted in Uncategorized
  • Cadila Pharmaceuticals Limited launches Risorine, world’s first boosted-Rifampicin containing fixed-dose combination
  • Risorine uses lower dose of Rifampicin (200 mg instead of 450 mg) but maintains the same efficacy. Addition of Piperine inhibits auto induction and maintains the same level throughout therapy. This is where it scores above the earlier modes of treatment of tuberculosis

 

Ahmedabad based Pharma major Cadila Pharmaceuticals has come up with a new product called RISORINE. Adding to the company’s long list of ‘firsts in the world’, Risorine promises to alter the way tuberculosis is treated at a global level. It is a boosted-Rifampicin containing fixed-dose combination product that has been approved in India for use as an anti-tubercular drug.

Risorine is of crucial importance because currently, tuberculosis is one of the major contagious diseases killing millions of people worldwide and has particularly devastating effects in the third world countries. And what is making the situation worse is that virtually no major initiative towards the improvement of the treatment of tuberculosis has been taken in recent years. It is this grim scenario that makes the efforts of Cadila Pharmaceuticals all the more significant.

Tuberculosis is considered to be a disease of the third world or developing countries. Southeast Asia region, with 4.97 million TB Cases, carries over one- third of the global burden of TB. Annually 1.8 million new cases are detected of which 5% TB patients are estimated to be HIV infected. WHO report reveals that more than 3.25 lakhs people in India had died of TB in 2005 alone. As regards the treatment burden for TB is concerned, it indirectly costs $3 billion to the society and direct cost is $300 million.

According to Ministry of Health and Family Welfare, India is the highest Tuberculosis burden country in the world having 2 deaths every 3 minutes. TB also is the most common opportunistic infection in patients infected with HIV. Lifetime risk of contracting Tuberculosis is five times more in HIV patients than normal population.

In the field of treatment of tuberculosis, Rifampicin has been a first line anti-tubercular drug for a long time now. It has been used for the chemotherapy of Tuberculosis since 1960s and it is known for causing lots of side effects. Also, the levels of Rifampicin in blood decrease over a period of time due to the auto-induction of drug metabolizing enzymes by Rifampicin. This results in sub-therapeutic levels of Rifampicin causing treatment failure in Tuberculosis. It is in such a scenario that Cadila Pharmaceuticals has come up with RISORINE, a boosted-Rifampicin containing fixed-dose combination product that has been approved in India for use as an anti-tubercular drug.

The novelty of RISORINE lies in the fact that it contains Piperine. Addition of Piperine inhibits auto induction and maintains same level throughout therapy. It also allows to use lower dose of Rifampicin (200 mg instead of 450 mg). It also has lower gastro-intestinal side effects. Risorine is the outcome of Public Private Partnership between Indian Institute of Integrative Medicine (Formerly known as Regional Research Laboratory), Jammu, an institute of Council of Scientific and Industrial Research (CSIR), Govt. of India and Cadila Pharmaceuticals Ltd.

In a multi-centric clinical trial conducted across India in patients with radiologically confirmed diagnosis of pulmonary tuberculosis, more than 90% of the patients treated with Risorine were cured of Tuberculosis with comparatively lesser side effects and better safety profile. The areas in which Risorine scores over the earlier modes of treatment are that it is not only cost effective but also safe and more effective.

At a time when the threat of tuberculosis still looms large over the society and the state is incurring huge expenditures for its treatment, the advent of Risorine surely comes as a boon. The huge number of tuberculosis cases detected annually in India can definitely be checked and a cost effective solution be provided with help of Risorine.

Expressing concern over the current state of tuberculosis treatment and also referring to the World Health Organisation (WHO) report released in March-2008, the chairman of Cadila Pharmaceuticals Mr. Indravadan Modi said, “Tuberclosis is a major cause of many illnesses and deaths worldwide. Globally, 9.2 million new cases and 1.7 million deaths from TB occurred in 2006. India is home to over 3.4 million tuberculosis patients – about one-fifth of the global figure – making it the most TB prevalent country.” But he also spoke enthusiastically about the new ray of hope that has emerged in the otherwise bleak arena of tuberculosis treatment, “In the given situation, the launch of RISORINE is our endeavor to combat Tuberculosis in a more efficient and cost effective way .The launch of RISORINE is also a step forward towards Cadila Pharmaceuticals’ philosophy to provide Quality medicine at an affordable price.”

One has to admit that Mr. Modi could not have been more correct. At a time when the Ahmedabad based pharma major, Cadila Pharmaceuticals, is already making waves with its ‘wonder drug’ Polycap, the unmatched features offered by RISORINE will certainly add a new dimension in the field of TB treatment globally.

About Cadila Pharmaceuticals Ltd.

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. It is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has  manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia.  Cadila Pharmaceuticals has recently emerged on the World map with the development of Polycap – a novel and world’s first drug combination for prevention of Cardiovascular Heart Disease.

CPL Biologicals is a newly formed company evolved from a joint venture by Cadila Pharmaceuticals Ltd and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals.  In addition, CPL Biologicals will establish manufacturing facilities in India and develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology.

Posted in Uncategorized

Ahmedabad, 29 November, 2010 – Ahmedabad based pharma major Cadila Pharmaceuticals Limited has received a prestigious Wellcome Trust Award under the new R&D for Affordable Healthcare in India initiative to support a phase III clinical trial of PolycapTM, a combination pill to reduce the risk of Cardiovascular diseases.

Cardio Vascular Diseases (CVD), predominantly heart disease and stroke, account for around 30% of all deaths around the world. The PolycapTM offers a primary prevention strategy to individuals who are at high risk for these illnesses.

PolycapTM comprises three blood pressure reducing agents, including a diuretic and a beta blocker, together with a cholesterol-lowering statin. All of the agents have been chosen based on the evidence of their reducing cardiovascular risk and generic drug status.

The combination pill has already been tested in over 2000 volunteers across 50 centers in India as part of The Indian PolycapTM Study (TIPS) published in the Lancet in 2009. Results from that phase II trial found that use of the drug reduces the risk of coronary heart disease by 62% and stroke by 48%.

Speaking of the award, Mr. Indravadan Modi, Chairman of Cadila Pharmaceuticals said, “We are delighted that our innovative product has gained recognition by the UK’s leading biomedical foundation, the Wellcome Trust. This award endorses our efforts in providing research-based revolutionary products in the cardio care segment.”

The Wellcome Trust award will support the study of at least 5,000 individuals with no previous history of heart attack or stroke. The placebo-controlled trial will recruit men over the age of 55 and women over 60 that have been identified as being at increased risk of CVD through a questionnaire based on family history and lifestyle factors. The investigators will assess whether taking PolycapTM for a period of five years can cut the risk of CVD, by monitoring the incidence of death due to heart attack, non-fatal heart attack, and non-fatal stroke.

Dr Nick Dunster, Senior Business Analyst at the Wellcome Trust, commented: “Cadila Pharmaceuticals has already reported positive results from previous clinical trials and we look forward to seeing how PolycapTM performs in this larger phase III trial. CVD is a global problem, so a drug that can cut the risk for susceptible individuals has the potential to make a huge impact on human health the world over, not just in India.”

About Cadila Pharmaceuticals Ltd.

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. It is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the World map with the development of Polycap – a novel and world’s first drug combination for prevention of Cardiovascular Heart Disease.

CPL Biologicals is a newly formed company evolved from a joint venture by Cadila Pharmaceuticals Ltd and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals. In addition, CPL Biologicals will establish manufacturing facilities in India and develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology.
www.cadilapharma.com

About The Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
www.wellcome.ac.uk

Posted in Uncategorized

September 25, Samba, Jammu:

Founded by the doyen of the Indian Pharmaceuticals industry Shri Indravadan A. Modi, Pharma Major Cadila Pharmaceuticals is all set to take a quantum leap by introducing new and innovative drugs in the global market in near future.

Cadila Pharmaceuticals has been research oriented company right from its inception is investing heavily in research activities targeting the key therapeutic areas like Tuberculosis, various types of cancer, novel vaccine adjuvants, Sepsis management and therapeutic vaccine for pancreatic cancer.

The company has one of the best Research and Development (R&D) setups in India, manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering.

Speaking about the company’s vision, philosophy and future plans Dr. Rajiv I Modi, Chairman and Managing Director said, “Cadila Pharmaceuticals will dedicatedly follow philosophy of the Founder Chairman  Shri I.A. Modi to offer quality medicines at an affordable price. The company, in recent past has introduced world’s first five-in-one innovative product ‘Polycap’ for Cardiovascular diseases (CVDs) and anti tuberculosis drug ‘Risorine’ with boosted Rifampicin which has better compliance less side effects. Continuing this trend, Cadila Pharmaceuticals will offer many more innovative products in time to come.”

Dr. Modi was interacting with media at Indravadan A. Modi memorial lecture series launch instituted by CSIR-Indian Institute of Integrative Medicine (IIIM) on the eve of 70th Foundation Day of the institute. Dr. Modi presided over this event and delivered presidential remarks.

Cadila Pharmaceuticals is the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed five more INDs from USFDA. Of the five INDs filed, one is for pulmonary tuberculosis; the trial is supported by Department of Biotechnology, Govt. of India. The rest four are for various types of cancers, e.g., Lung Cancer, Prostrate cancer, Bladder Cancer and Melanoma. Thus all the INDs are for providing solutions to major global health care problems. The clinical trials on Prostate cancer, Lung cancer and Bladder cancer are supported by Department of Science and Technology to encourage innovations.

With a view to boost the research activities, the company has also entered in Public-Private partnerships with premier research institutions of the country  for developing diagnostic, preventive and curative pharmaceutical and diagnostic products. Innovations that have resulted from such partnerships include ‘Immuvac’ – a unique immuno-modulator that has various applications including reducing duration of therapy for treatment of multi drug resistant tuberculosis and multibacillary leprosy, ‘NEVA’ – a rapid HIV detection kit and more recently Risorine – the world’s first boosted-Rifampicin containing fixed-dose combination for use as an anti-tubercular drug.

Cadila Pharmaceuticals Ltd. has also entered into strategic alliances to broaden its horizons. CPL Biologicals, a joint venture with Novavax, Inc. USA formed in 2009, will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India. In addition, CPL Biologicals has set up manufacturing facility at Dholka, Ahmedabad in the state of Gujarat, to develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax’s virus-like-particle (VLP) vaccine technology.  StemCyte India which is into Umbilical Cord Blood Stem Cells Banking is a joint venture of Cadila Pharmaceuticals with StemCyte Inc. USA and Apollo group. Cadila Pharmaceuticals has also entered into a joint venture with Apollo Hospitals Group to manage Apollo Hospital, Ahmedabad.

Posted in Uncategorized

Cadila Pharmaceuticals Limited, one of India’s largest privately held pharmaceuticals company, and UK-based antibiotics discovery company, Helperby Therapeutics have signed a joint agreement on Antibiotic Drug Resistance Research & Development. Global market size of antibiotics is estimated to be around $69 billion.

Described as the most important innovation in the discovery of new antibiotics since Alexander Fleming’s original breakthrough more than 80 years ago, this announcement is a major breakthrough in the fight against resistance with the discovery of patented ‘resistance breaker’ compounds. These new compounds are called Antibiotic Resistance Breakers. When an Antibiotic Resistance Breaker is combined with an old obsolete antibiotic, it can rejuvenate it and make it active against highly resistant bacteria. Antibiotic Resistance Breakers can potentially rescue several different classes of antibiotics. Furthermore, this approach requires the development of fewer novel compounds, is less risky and less costly than the traditional “one antibiotic” route.

Elaborating on this tie up, Cadila Pharmaceuticals’ Chairman and Managing Director, Dr. Rajiv I Modi said, “The Founder Chairman of our company, Shri IA Modi, believed in providing affordable medicines for the masses through innovative and cutting-edge research & development (R&D). This discovery will open new avenues against resistant organisms and is very timely in view of global concerns about rapidly growing bacterial resistance against current antibiotics. Cadila Pharmaceuticals’ collaboration with Helperby can help the mankind win the battle against the microbes and hopefully save millions of lives in coming years.”

Travelling with the UK’s Trade Delegation to India led by Prime Minister David Cameron, Helperby signed its first major licensing deal with Indian pharma giant Cadila Pharmaceuticals to take the compound through further clinical trials, approvals and into commercialisation. Helperby will supply Cadila Pharmaceuticals Ltd. with Antibiotic Resistance Breakers whilst Cadila Pharmaceuticals Ltd. will develop the combinations with old antibiotics. The deal value was undisclosed but could contribute to Helperby scaling up in the UK to a potential £500 million operation, creating employment for 500-1000 persons by 2019.

Helperby, a spin-out of the UK’s University of London, St George’s Hospital has been working for the past 12 years on ways to tackle antibiotic resistance and has discovered a new series of potent, fast-acting drugs which rescue old antibiotics. Instead of targeting multiplying bacteria, the research team focused on non-multiplying, dormant bacteria. Developing antibiotics that specifically target these root-like bacteria has never been done before – in fact conventional methods of screening have consistently missed these promising candidate drugs.

Cadila Pharmaceuticals will take the new discovery through phase III and into commercialisation. The company is now actively considering a presence in the UK with a corresponding programme for UK microbiologists as part of the collaboration. The licensing agreement will allow Cadila Pharmaceuticals to bring the first product to market in around 18 months time.

About Cadila Pharmaceuticals www.cadilapharma.com

With a turnover of Rs 1200 crore, Cadila Pharmaceuticals is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, anti-diabetics and immunologicals. It has more than 7000 employees across the globe.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

About Helperby Therapeutics www.helperby.com

Helperby Therapeutics is a spin-out drug discovery company from the University of London, St George’s Hospital, and has been working for the last 12 years developing antibiotics that specifically target dormant bacteria, a technique that has never been done before. This pioneering discovery by Professor Anthony Coates and Dr Yanmin Hu is a unique, patented approach that has been found to be extraordinarily effective in breaking resistance when Helperby’s compounds are combined with old antibiotics.

Posted in Uncategorized

Cadila Pharmaceuticals Limited, one of India’s largest privately held pharmaceuticals company, has launched for the first time in the world, Mycidac-C, an affordable, unique and innovative drug for the treatment of Lung Cancer.

Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets Desmocolin-3, a novel target.

This is a first in the class active immunotherapy as well as drug targeting Desmocollin-3. It is a breakthrough in the management of squamous cell NSCLC. There has been no significant innovation in management of squamous NSCLC since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy.

As per the World Health Organisation (WHO) report, approximately 1.25 million people are diagnosed with lung cancer every year worldwide. Around 30% of them suffer from squamous NSCLC. Lung Cancer kills more people than the three next commonest cancers combined.

This is in line with the vision of Shri I A Modi, Founder Chairman, Cadila Pharmaceuticals Ltd., to make affordable healthcare accessible to the masses for alleviating human suffering. Mycidac-C can be administered easily by trained paramedics, thus further reducing the cost of hospitalisation associated with other cancer therapy.

Speaking at the launch, Dr Rajiv I Modi, Chairman and Managing Director of Cadila Pharmaceuticals said, “It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years.”

Dr T. Ramasami, Secretary to the Government of India, Department of Science and Technology also commented: “Lung cancer is a major killer among all cancers. In this scenario, Mycidac-C is a new hope for the patients suffering form lung cancer, particularly for Indian patients.”

About Cadila Pharmaceuticals www.cadilapharma.com

With a turnover of Rs 1200 crore, Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, anti-diabetics and immunologicals. It has more than seven thousand employees across the globe.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

Posted in Uncategorized
Cadila Pharmaceuticals to observe World TB Day
Multi-city activities to raise awareness on killer disease

More than 50 lakh cases examined in Gujarat alone; Over 10 lakh TB patients on DOTS treatment till June 2014

March 23, 2015: Cadila Pharmaceuticals Limited – one of India’s largest privately held pharmaceuticals companies is planning various activities across Gujarat to raise awareness about Tuberculosis on World TB Day (March 24). The activities will engage doctors, hospitals, medical colleges and youth through awareness rallies and marathons, in-clinic posters, CMEs (continuous medical education) and skits/street plays. The awareness campaign will highlight the importance of early diagnosis, regular dosage, completion of treatment and patient compliance to help control the disease.

Since the inception of Revised National TB Control Programme (RNTCP), in Gujarat alone (as on June 2014), more than 50 lakh TB suspects have been examined and over 10 lakh TB patients have been put on DOTS treatment according to statistics from Health and Family Welfare Department, Government of Gujarat.

“Tuberculosis is closely associated with socio-economic conditions like, nutrition, living standards, and health systems. The need of the hour is to discuss the status of Tuberculosis disease control efforts and to strongly advocate and create awareness to reduce the stigma associated with the disease, so that suspected cases can take pro-active steps for diagnosis. It is a collective responsibility of all of us to contribute to the comprehensive TB control program and help root out the disease from the country”, said Dr. B.M. Soni, Honorary Secretary,
Gujarat State TB Association.

Tuberculosis is an infectious bacterial disease caused by Mycobacterium Tuberculosis, which affects the lungs most commonly. It is a highly contagious bacterial infection that can spread quickly if not caught, isolated and treated early. A TB patient can infect through breathing, coughing, talking, singing, sneezing etc.

Worldwide too, Tuberculosis is a killer disease with almost 1.5 million deaths recorded in 2013. According to the World Health Organisation Report 2012, India is the highest TB burden country with an estimated incidence of 2.2 million cases out of a global incidence of 8.6 million cases. India and China alone accounted for 26% and 12% of total cases, respectively. It is also estimated that about 40% of the Indian population is infected with TB bacteria, with the vast majority of them having latent rather than active TB.

Cadila Pharmaceuticals Ltd. is amongst the few companies worldwide that has continued to invest in research and development and is committed to Government of India’s ‘TB-Mission 2020’, which seeks to eradicate Tuberculosis from the country. Cadila Pharmaceuticals, driven by its vision of providing world-class, yet affordable medicines, had launched Risorine, the world’s first anti-tubercular drug with boosted Rifampicin, in the year 2009. Risorine uses lower dose of Rifampicin (200 mg instead of 450 mg) but maintains the same efficacy. The drug has so far, been successfully administered to more than 50,000 TB patients. Cadila Pharmaceuticals was one of the first companies to introduce Mycobutol and P-Zide in India and has been serving the Indian medical fraternity for over 30 years with a complete range of Anti-TB drugs.

About Cadila Pharmaceuticals Limited: www.cadilapharma.com
Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world. The company has successfully launched three global-first innovations, Polycap (first polypill for cardiovascular diseases), Risorine (first boosted-Rifampicin for Tuberculosis treatment) and Mycidac-C (first active immunotherapy for lung cancer). Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

Posted in Uncategorized
A team of doctors from Kaka-Ba Hospitals rendered the services to commemorate Doctors’ Day

Highlights:

  • Free medical check-up and treatment camp was held in Bhat village
  • Team of 20 doctors and 15 Para medical staff associated with Kaka-Ba hospital extended their services to commemorate Doctors’ Day (Observed every year on July 1)
  • Around 1,000 patients of Bhat and surrounding villages like Badarkha, Rampur, Mota Chhapra, Kasindra, Visalpur benefited from the medical camp
  • Kaka-Ba Hospital, an initiative of Shri Indravadan Modi, the Founder Chairman of Cadila Pharmaceuticals Ltd, has emerged as successful rural healthcare model
  • Till date, Kaka-Ba Hospital has treated more than 6 lakh patients and performed more than 3,000 plastic surgeries free of cost

June 28, 2015: As a part of its Corporate Social Responsibility (CSR) initiatives, Cadila Pharmaceuticals Ltd, one of the largest privately held pharmaceuticals companies in India and Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust organised a free medical check-up and treatment camp on Sunday, June 28 to provide healthcare support to the locals. The medical camp was organised at Bhat village in Ahmedabad. A team of doctors from Kaka-Ba Hospitals rendered the services to commemorate Doctors’ Day (Observed every year on July 1). Around 1,000 patients of Bhat and surrounding villages like Badarkha, Rampur, Mota Chhapra, Kasindra, Visalpur benefited from this noble initiative.

A team of 20 doctors including cardiologists, gynaecologists, ophthalmologists, orthopaedics, dermatologists, paediatricians, ENT specialists, gastroenterologists, endocrinologists, general surgeons and 15 Para medical staff from Kaka-Ba Hospital rendered their services in the camp. Patients underwent health checkups by the team of specialist doctors and were given consultations and medicine free of cost.

Speaking on this noble initiative, Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd said “Cadila Pharmaceuticals is committed towards inclusive and sustainable growth. As a responsible Corporate Citizen, Cadila Pharmaceuticals undertakes a number of CSR activities in larger interest of the community, especially in the area of health, education, women empowerment and childcare apart from supporting a number of NGOs who work with underprivileged people. Cadila Pharmaceuticals will continue to support more such camps in close vicinity of Bhat and Dholka.”

Dr. Bharat Champaneria, Chief Coordinator and Superintendent, Kaka-Ba Hospital said, “`Doctors’ Day’ is very special for every medical practitioner. Ahead of this special day, doctors from Kaka-Ba Hospitals feel so much proud and satisfaction by rendering healthcare services to locals. Kaka-Ba Hospital has played a pivotal role in comprehensive and sustainable rural development and has emerged as a successful rural healthcare model. Till date it has treated more than six lakh patients. The hospital has been organizing medical camps regularly in economically backward tribal region of Bharuch (Hansot village), Gujarat and the surrounding rural areas for screening, diagnosis and treatment and has been able to save a number of lives. The hospital has also performed more than 3,000 plastic surgeries free of cost.”

Doctor’s Day is observed on 1st of July on the birth and death anniversary of the most famous physician of India Dr. Bidhan Chandra Roy (Dr. B C Roy) to pay honour and salutes the spirit of his dedication. Dr. B C Roy was awarded ‘Bharat Ratna’ on 4th February, 1961. First Doctor’s Day was celebrated in 1991. The annual celebration of this day helps common public to get aware about the roles, importance and the precious care of the doctors.

Kaka-Ba Hospital, established in 1985 at Hansot, Dist- Bharuch, Gujarat is the hub of CSR activities run by Cadila Pharmaceuticals. Established by the founder of Cadila Pharmaceuticals and philanthropist, Shri I.A. Modi, Kaka-Ba Hospital, in a span of three decade, has emerged as a blessing for poor, needy patients of Bharuch district and nearby areas. Serving and saving precious lives, more than 6 lakh patients have been treated by the hospital for various ailments, till date.

About Cadila Pharmaceuticals Limited – www.cadilapharma.com

Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

About Kaka-Ba Hospital www.kakabatrust.org

Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. He set up the hospital in 1985 with a vision for it play a pivotal role in multifold, holistic rural development, impart latest and quality medical services, create health and hygiene awareness, education and welfare of women and children.
In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. Till date the hospital has treated more than 6 lacs patients and has saved hundreds of valuable lives.
With a view to serve people better and provide latest medical services, a number of new facilities are being introduced. The hospital will soon be equipped with MRI facility whereby patients from adjoining cities and towns like Ankleshwar and Bharuch will benefit. All these services will be provided at very nominal charges or free to the really deserving.

Posted in Uncategorized

Highlights:

  • Free medical check-up and treatment camp held in Transad village in Dholka Taluka
  • Team of 20 doctors and 15 Paramedical staff from Kaka-Ba Hospital extended their services
  • More than 1000 residents from Transad and nearby villages like Nesda, Paldi, Pisawada, Bhetawada Rampur, Dadusar Virdi, Ingoli benefited from the medical camp
  • Kaka-Ba Hospital, an initiative of Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd, has emerged as successful rural healthcare model
  • Till date, Kaka-Ba Hospital has treated more than 6 lakh patients and performed more than 3,000 plastic surgeries free of cost

 

September 21, 2015: As a part of its Corporate Social Responsibility (CSR) initiatives, Cadila Pharmaceuticals Ltd, one of the largest privately held pharmaceuticals companies in India and Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust organised a free medical check-up and treatment camp on Sunday, September 20 to provide healthcare support to residents of local villages. The medical camp was organised at Sheth Shri D K Shah High School, Transad village of Dholka Taluka in Ahmedabad. More than Around 1000 people from Transad and nearby villages like Pisawada, Bhetawada , Virdi, Ingoli benefited from this noble initiative.

A team of 10 20 doctors including cardiologists, gynaecologists, ophthalmologists, orthopaedics, dermatologists, paediatricians, ENT specialists, gastroenterologists, endocrinologists, general surgeons and 15 Paramedical staff from Kaka-Ba Hospital rendered their services in the camp. Patients underwent health checkups by the team of specialist doctors and were given consultations and medicine free of cost.

More than 100 patients have been diagnosed for further treatment surgeries related to Cataract, gynaecology , Orthopeadic, Urology etc. , who will be treated at Kaka-Ba hospital free of cost during in phased manner during next three months.

Speaking on these important initiatives Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd said “Cadila Pharmaceuticals is committed towards inclusive and sustainable growth. Under the aegis of Kaka-Ba and Kala-Budh Public Charitable Trust, we use a holistic model of development and undertake a number of CSR activities in larger interest of the community, especially in the area of health, education, women empowerment and childcare apart from supporting a few other Not for Profit efforts . Cadila Pharmaceuticals will continue to support more such CSR initiatives.”‎

Dr. Bharat Champaneria, Chief Coordinator and Superintendent, Kaka-Ba Hospital said, “Kaka-Ba Hospital has played a pivotal role in comprehensive and sustainable rural development and has emerged as a successful rural healthcare model. Till date it has treated more than six lakh patients. The hospital has been organising medical camps regularly in economically backward region for screening, diagnosis and treatment and has been able to save a number of lives. The hospital has also performed more than 3,000 plastic surgeries free of cost.”

Kaka-Ba Hospital, established in 1985 at Hansot, Dist- Bharuch, Gujarat is the hub of CSR activities run by Cadila Pharmaceuticals. Established by the founder of Cadila Pharmaceuticals and philanthropist, Shri I.A. Modi, Kaka-Ba Hospital, in a span of three decades, has emerged as a blessing for poor, needy patients of Bharuch district and nearby areas. Serving and saving precious lives, more than 6 lakh patients have been treated by the hospital for various ailments, till date.

About Cadila Pharmaceuticals Limited – www.cadilapharma.com

Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

About Kaka-Ba Hospital www.kakabatrust.org

Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. He set up the hospital in 1985 with a vision for it play a pivotal role in multifold, holistic rural development, impart latest and quality medical services, create health and hygiene awareness, education and welfare of women and children.
In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. Till date the hospital has treated more than 6 lakh patients and has saved hundreds of valuable lives.
With a view to serve people better and provide latest medical services, a number of new facilities are being introduced. The hospital will soon be equipped with MRI facility whereby patients from adjoining cities and towns like Ankleshwar and Bharuch will benefit. All these services will be provided at very nominal charges or free to the really deserving.

Posted in Uncategorized
More than 3,000 plastic surgeries free of cost has been performed by the hospital

September 29, 2015: Kaka-Ba Hospital an initiative of Cadila Pharmaceuticals Ltd has accomplished more than 100 surgeries free of cost to the needy patients of Dholka and Bhat medical camps. The hospital performed 80 cataract operations, 10 dental surgeries, 5 orthopedic and 5 gynecology surgeries till t 26-27 September, 2015 at its premises in Hansot, Bharuch. Moreover, free transportation, food, accommodation was also arranged for the patients by Cadila Pharmaceuticals Ltd. Till date, Kaka-Ba Hospital has treated over 6 lakh patients and performed more than 3,000 plastic surgeries free of cost.

Kaka-Ba Hospital and Cadila Pharmaceuticals Ltd had organised two free medical checkup camps at Tradand ( Near Dholka) and Bhat in Ahmedabad on June 28 and Sept 210, 2015. More than 1,800 residents benefited from the camps while around 150 patients were diagnosed and required further treatment.

All 100 patients were taken in two three batches of 50 each and upon successful completion of the treatment were discharged from the hospital. Timely follow ups have been done and it is found that all the patients are in good health and no complication is reported from any of the patients because of proper care from the hospital. The third next batch of 50 remaining patients will be taken for further treatment in the month of OctoberOctober-December.

Kaka-Ba Hospital is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. Established in 1985, the hospital is hub of CSR activities run by Cadila Pharmaceuticals. In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. During last three years , the hospital infrastructure has been developed and expanded in such a way that now it has capacity to accommodate apprx 100 patients. Operation theatre facilities for General surgeries ,Gynec suegeries and Opthalmic surgeries have been upgraded and equipped with ultra modern equipments.

Speaking on these important initiatives, Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd said “Under the aegis of Kaka-Ba and Kala-Budh Public Charitable Trust, we use a holistic model of development and undertake a number of CSR activities in larger interest of the community, especially in the area of health, education, women empowerment and childcare apart from supporting a few other Not for Profit efforts. Cadila Pharmaceuticals will continue to support more such CSR initiatives.”‎

Dr. Bharat Champaneria, Chief Coordinator and Superintendent, Kaka-Ba Hospital said, “Kaka-Ba Hospital has played a pivotal role in comprehensive and sustainable rural development and has emerged as a successful rural healthcare model. Till date it has treated more than six lakh patients. The hospital has been organising medical camps regularly in economically backward region for screening, diagnosis and treatment and has been able to save a number of lives. The hospital has also performed more than 3,000 plastic surgeries free of cost and the campaign is still going on.”

About Cadila Pharmaceuticals Limited – www.cadilapharma.com

Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world. Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

About Kaka-Ba Hospital www.kakabatrust.org

Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. He set up the hospital in 1985 with a vision for it play a pivotal role in multifold, holistic rural development, impart latest and quality medical services, create health and hygiene awareness, education and welfare of women and children.
In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. Till date the hospital has treated more than 6 lakh patients and has saved hundreds of valuable lives.
With a view to serve people better and provide latest medical services, a number of new facilities are being introduced. The hospital will soon be equipped with MRI facility whereby patients from adjoining cities and towns like Ankleshwar and Bharuch will benefit. All these services will be provided at very nominal charges or free to the really deserving.

Posted in Uncategorized

Sermon on Sankhya Yog from 25th November – 1st December

A spiritual discussion of philosophy of ‘Geeta Jeevan Sanhita: Astitva no Utsav – Shri Krishna ni Sathe’ is being held on third death anniversary of Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd and a legend who was ardent believer in Indian philosophy. This seven day program will see a thought provoking talk on Bhagwad Geeta’s second chapter Sankhya Yog by eminent preacher Pujyashri Bhupendrabhai Pandya who will also put a light on ideology of liberation and self-consciousness.

Geeta Jeevan Sanhita’ is organised by Cadila Pharmaceuticals Ltd at Gujarat University Convention Hall, 132 ft Ring Road, Helmet Cross Roads from November 25 – December 1 during 4:00-7:00 pm.

Shri Indravadan Modi always lived his life as per principals of our great religious books. He was ardent believer in Indian philosophy and spirituality. He firmly believed that Ved, Puran and other holy books of Hindu religion prosper human life and everyone of our society should get benefited with this traditional knowledge. Cadila Pharmaceuticals family follows this vision of Shri Indravadan Modi and is committed to carry forward the same.

Bhagwad Geeta, a dialogue between Shri Krishna and Arjun in the battlefield of Kurukshetra before starting of Mahabharat war 5000 BC, is a paramount holy book elaborating spirituality and lessons of good life to all mankind. The philosophy elaborated in this book is prevalent in today’s modern life also.

Posted in Uncategorized

More than ____ plastic surgeries and ____ pediatric dental surgeries successfully completed by eminent doctors from Kaka-Ba Hospital, Operation Rainbow Canada, Indo – Africa Charitable Society

Highlights:

  • Team of __ eminent international repute doctors from Operation Rainbow Canada, Indo – Africa Charitable Society gave their service free of cost during Nov 22 – Dec 2 at Kaka-Ba Hospital, Hansot
  • Over ___ plastic surgeries and ____ pediatric dental surgeries to be undertaken by team of eminent doctors from Kaka-Ba Hospital, Operation Rainbow Canada, Indo – Africa Charitable Society
  • Kaka-Ba Hospital, an initiative of Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd, has emerged as successful rural healthcare model
  • Till date, Kaka-Ba Hospital has treated more than 6 lakh patients and performed more than 3,000 plastic surgeries free of cost

November 27, 2015: CSR initiative of Cadila Pharmaceuticals Ltd, Kaka-Ba Hospital has organised free plastic surgeries & pediatric dental surgeries camp in Gujarat at its hospital in Hansot, Ankleshwar in association with Operation Rainbow Canada & Indo – Africa Charitable Society. More than ___ plastic surgeries and ____ pediatric dental surgeries to be undertaken by team of eminent doctors from Kaka-Ba Hospital, Operation Rainbow Canada, Indo – Africa Charitable Society including world renowned plastic surgeon Dr. Kimit Rai during Nov 22 – Dec 2 at Kaka-Ba Hospital, Hansot. This noble initiative will benefit hundreds of people in nearby areas.

The team of 35 international repute doctors travelling with Operation Rainbow Canada, Indo – Africa Charitable Society will conduct all the surgeries free of cost using special surgical method for the 1st time in Gujarat. The team will also share their valuable experiences and train doctors of Kaka-Ba Hospital with best global healthcare practices and special surgical method for plastic surgery.

Dr. Bharat Champaneria, Chief Coordinator and Superintendent, Kaka-Ba Hospital said, “First time in Gujarat such a noble initiative has been organised at this scale. The team will do over ___ surgeries during Nov 22 – Dec 2 with best global surgical method. The new surgical method ensures high level of sterilisation, reduces infection and ensures fast recovery and requires minimum use of antibiotics. We will organise more such initiatives including exchange programs with an aim to bring excellence in healthcare.”

Kaka-Ba Hospital has played a pivotal role in comprehensive and sustainable rural development and has emerged as a successful rural healthcare model. Till date it has treated more than six lakh patients. The hospital has also performed more than 3,000 plastic surgeries free of cost. During this campaign, Kaka-Ba Hospital along with doctors from Operation Rainbow Canada & Indo – Africa Charitable Society visited Hansot and nearby regions and have identified 500 patients for free pediatric dental and plastic surgeries which will be completed in the next 3-4 months.

Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd said, “Cadila Pharmaceuticals is committed towards inclusive and sustainable growth. Under the aegis of Kaka-Ba and Kala-Budh Public Charitable Trust, we use a holistic model of development and undertake a number of CSR activities in the larger interest of the community, especially in the area of health, education, women empowerment and childcare, apart from supporting a few other Not for Profit efforts . Cadila Pharmaceuticals will continue to support more such CSR initiatives.”‎

Kaka-Ba Hospital, established in 1985 at Hansot, Dist- Bharuch, Gujarat is the hub of CSR activities run by Cadila Pharmaceuticals. Established by the founder of Cadila Pharmaceuticals and philanthropist, Shri I.A. Modi, Kaka-Ba Hospital, in a span of three decades, has emerged as a blessing for poor, needy patients of Bharuch district and nearby areas. Serving and saving precious lives, more than 6 lakh patients have been treated by the hospital for various ailments, till date.

About Kaka-Ba Hospital www.kakabatrust.org

Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. He set up the hospital in 1985 with a vision for it play a pivotal role in multifold, holistic rural development, impart latest and quality medical services, create health and hygiene awareness, education and welfare of women and children.
In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. Till date the hospital has treated more than 6 lakh patients and has saved hundreds of valuable lives.
With a view to serve people better and provide latest medical services, a number of new facilities are being introduced. The hospital will soon be equipped with MRI facility whereby patients from adjoining cities and towns like Ankleshwar and Bharuch will benefit. All these services will be provided at very nominal charges or free to the really deserving.

About Cadila Pharmaceuticals Limited – www.cadilapharma.com

Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe. It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world. Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

Posted in Uncategorized
Highlights:
  • Free medical check-up and treatment camp held in Ankleshwar
  • Team of 25 doctors and 50 Paramedical staff including cardiologists, gynaecologists, ophthalmologists, orthopaedics, dermatologists, paediatricians, ENT specialists etc associated with Kaka-Ba Hospital extended their services
  • Around 1200 residents from Ankleshwar and nearby villages like Diva, Piraman, Gadkhol, Kosamadi and Amboli benefited from the medical camp
  • Kaka-Ba Hospital, an initiative of Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd, has emerged as successful rural healthcare model
  • Till date, Kaka-Ba Hospital has treated more than 6 lakh patients and performed more than 4,000 plastic surgeries free of cost

As a part of its Corporate Social Responsibility (CSR) initiatives, Cadila Pharmaceuticals Ltd, one of the largest privately held pharmaceuticals companies in India and Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust organised a free medical check-up and treatment camp on Sunday, May 29, 2016 to provide healthcare support to residents of local villages in Ankleshwar and Bharuch. The medical camp was organised at Ramanbhai Muljibhai Patel Wadi, Near Bharuchi Naka in Ankleshwar. A team of 25 doctors and 50 Paramedical staff from Kaka-Ba Hospital extended their services in the camp. Around 1200 people from Ankleshwar and nearby villages like Diva, Piraman, Gadkhol, Kosamadai and Amboli benefited from this noble initiative.

A team of 25 doctors including cardiologists, gynaecologists, ophthalmologists, orthopaedics, dermatologists, paediatricians, ENT specialists, gastroenterologists, endocrinologists, general surgeons and 50 Paramedical staff from Kaka-Ba Hospital rendered their services in the camp. Patients underwent health checkups by the team of specialist doctors and were given consultations and medicine free of cost.

Speaking on these important initiatives Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd said “Cadila Pharmaceuticals is committed towards inclusive and sustainable growth. Under the aegis of Kaka-Ba and Kala-Budh Public Charitable Trust, we use a holistic model of development and undertake a number of CSR activities in larger interest of the community, especially in the area of health, education, women empowerment and childcare apart from supporting a few  other Not for Profit efforts . Cadila Pharmaceuticals will continue to support more such CSR initiatives.”

Dr. Bharat Champaneria, Chief Coordinator and Superintendent, Kaka-Ba Hospital said, “Doctors associated with Kaka-Ba Hospitals feel so much proud and derive satisfaction by rendering healthcare services to locals at this free medical camp. Kaka-Ba Hospital has played a pivotal role in comprehensive and sustainable rural development and has emerged as a successful rural healthcare model. Till date, it has treated more than six lakh patients. The hospital has been organizing medical camps regularly in economically backward tribal region of Bharuch (Hansot village), Gujarat and the surrounding rural areas for screening, diagnosis and treatment and has been able to save a number of lives. The hospital has also performed more than 4,000 plastic surgeries free of cost.”

Kaka-Ba Hospital, established in 1985 at Hansot, Dist- Bharuch, Gujarat is the hub of CSR activities run by Cadila Pharmaceuticals. Established by the founder of Cadila Pharmaceuticals and philanthropist, Shri I.A. Modi, Kaka-Ba Hospital, in a span of three decades, has emerged as a blessing for poor, needy patients of Bharuch district and nearby areas. Serving and saving precious lives, more than 6 lakh patients have been treated by the hospital for various ailments, till date.

About Cadila Pharmaceuticals Limited – www.cadilapharma.com

Cadila Pharmaceuticals is one of the largest privately held pharmaceuticals companies in India, headquartered at Ahmedabad, Gujarat, India. Established in 1951, the company develops and manufactures pharmaceutical products and sells and distributes these in all major markets across the globe.  It is an integrated healthcare solutions provider with a comprehensive therapeutic basket including oncology, pulmonology, neurology and cardiovascular.

Cadila Pharmaceuticals is a research and innovation driven company and has collaborations with premier academic and research-based organisations across the world. Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

About Kaka-Ba Hospital – www.kakabatrust.org

Kaka-Ba Hospital, run by Kaka-Ba and Kala-Budh Public Charitable Trust is an initiative by renowned industrialist-cum philanthropist and one of the pioneers of Indian Pharmaceutical industry, Shri Indravadan Modi, Founder Chairman of Cadila Pharmaceuticals Ltd. He set up the hospital in 1985 with a vision for it play a pivotal role in multifold, holistic rural development, impart latest and quality medical services, create health and hygiene awareness, education and welfare of women and children.

In last three decades of its existence, Kaka-Ba Hospital has been imparting quality healthcare services. Till date the hospital has treated more than 6 lacs patients and has saved hundreds of valuable lives.

With a view to serve people better and provide latest medical services, a number of new facilities are being introduced. The hospital will soon be equipped with MRI facility whereby patients from adjoining cities and towns like Ankleshwar and Bharuch will benefit. All these services will be provided at very nominal charges or free to the really deserving.

Posted in Uncategorized
Counterfeit Drugs: In case of any information on /or availability of counterfeit products... Read More © 2017 Cadila Pharmaceuticals all right reserved
Corporate identification No : U24231GJ1991PLC015132
Cadila Pharmaceuticals